Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
NCT ID: NCT00143026
Last Updated: 2017-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
184 participants
INTERVENTIONAL
2005-07-31
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
NCT00134966
Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease
NCT06236230
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
NCT07227896
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
NCT01296464
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
NCT04990284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carbidopa, levodopa, entacapone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Motor functions must be regarded as non-disabling by the patient
Exclusion Criteria
* History of dyskinesia
* Previous or current use of entacapone or tolcapone
* Unstable Parkinson's disease patients requiring/receiving regimens of levodopa
* Subjects taking levodopa/DDCI controlled release or extended release formulations
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Adelaide Hospital
Adelaide, , Australia
Watkins Medical Center
Brisbane, , Australia
Central Coast Neuroscience Research
Gosford, , Australia
Heidelberg Repatriation Hospital
Melbourne, , Australia
Monash Medical Centre
Melbourne, , Australia
Sir Charles Gairdner Hospital
Perth, , Australia
Concord Hospital
Sydney, , Australia
Southern Neurology, St. George Private Hospital
Sydney, , Australia
Westmead Hospital
Sydney, , Australia
St. Luke's Medical Centre
Manila, , Philippines
University of Santo Tomas Hospital
Manila, , Philippines
Chang Gung Memorial Hospital
Linkou District, , Taiwan
Kaohsiung Medical University, Chung-Ho Memorial Hospital
Linkou District, , Taiwan
National Taiwan University Hospital
Linkou District, , Taiwan
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Maharaj Nakorn Chiangmai Hospital
Bangkok, , Thailand
Pharmongkutklao Army Hospital
Bangkok, , Thailand
Siriraj Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CELC200A2406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.